Remacemide

Remacemide is a pharmacological agent that was initially developed for the treatment of epilepsy. It is a low-affinity, non-competitive NMDA receptor antagonist. Remacemide and its major metabolite, FPL 12495AA, have been shown to have neuroprotective effects in animal models of neurodegenerative diseases such as Parkinson's disease and Huntington's disease. However, clinical trials in humans have not shown significant benefits, and development of the drug has been discontinued.

Pharmacology

Remacemide acts as a non-competitive antagonist at the NMDA receptor, a type of ionotropic glutamate receptor. It has a low affinity for the receptor, which means it does not bind strongly and can be easily displaced. This is in contrast to high-affinity NMDA receptor antagonists, which bind tightly and are not easily displaced.

Remacemide's major metabolite, FPL 12495AA, also acts as a non-competitive NMDA receptor antagonist. Both remacemide and FPL 12495AA have been shown to have neuroprotective effects in animal models of neurodegenerative diseases.

Clinical trials

Remacemide has been tested in clinical trials for several conditions, including epilepsy, Parkinson's disease, and Huntington's disease. However, these trials have not shown significant benefits.

In trials for epilepsy, remacemide was found to be less effective than other available treatments. In trials for Parkinson's disease and Huntington's disease, remacemide did not show significant benefits over placebo.

As a result of these findings, development of remacemide has been discontinued.

See also

• NMDA receptor antagonist
• Neurodegenerative diseases
• Epilepsy
• Parkinson's disease
• Huntington's disease

• 
  Remacemide